Close Menu

NEW YORK – NeuMoDx confirmed today it has received CE-IVD marking on assays to detect and quantify levels of hepatitis B virus and hepatitis C virus. The two assays are now available in Europe.

The Ann Arbor, Michigan-based firm is focused on high-volume central laboratory customers, and the HBV and HCV tests could be particularly useful to labs serving immunocompromised populations or monitoring HBV DNA and HCV RNA titers for therapy management, the firm noted in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.